Altre lingue Odyssey Health, Inc.

Azioni

ODYY

US67612C1027

Mercato chiuso - OTC Markets Altri mercati azionari 21:15:28 06/06/2024			Variaz. 5gg	Var. 1 gen.
0,028 ^USD	-9,52%		-20,85%	-71,90%

22/03	Odyssey Health, Inc. riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 31 gennaio 2024	CI
2023	Oragenics, Inc. (NYSEAM:OGEN) ha completato l'acquisizione delle Attività relative alle terapie farmacologiche neurologiche proprietarie e alle tecnologie di Odyssey Health, Inc.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	22/03
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	28/12
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	15/12
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	30/10/23
Odyssey Health, Inc. Announces the Resignation of John Gandolfo as Director	06/10/23
Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate	06/10/23
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	05/10/23
Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS	23/08/23
AM Best Upgrades Credit Ratings of Odyssey Group Holdings, Inc.'s Members	07/07/23
Odyssey Health, Inc. executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.	28/06/23
Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	14/06/23
ODYSSEY HEALTH, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	04/04/23
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment	30/03/23
ODYSSEY HEALTH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	17/03/23
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	17/03/23
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	17/03/23
Odyssey Health, Inc. Forms Community-Based Partnership with David R. Metcalf Foundation for Military Concussion Research	07/02/23
ODYSSEY HEALTH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	13/01/23
Odyssey Health, Inc. Appoints Jeffrey Conroy as Director	13/01/23
Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote	12/01/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Odyssey Health, Inc.

Azioni

ODYY

US67612C1027

Altre lingue

Filtri